Side-by-side comparison of AI visibility scores, market position, and capabilities
Steris plc (STE) reported ~$5.5B revenue in FY2024. Global leader in sterilization, decontamination, and infection prevention products and services for healthcare and life sciences. HQ: Dublin / Mentor, OH.
STERIS plc is the global leader in sterilization, reprocessing, and decontamination services and products for the healthcare and life sciences industries. The company provides the steam sterilizers, hydrogen peroxide sterilizers, endoscope reprocessors, and facility cleaning products that make surgical equipment safe to reuse — a critical but often invisible part of healthcare operations. STERIS also offers sterilization contract services for medical device manufacturers, processing implants, surgical instruments, and single-use devices at over 60 facilities worldwide.
mRNA pioneer with $3.2B FY2024 revenue (down from $18.4B 2022 COVID peak); mRESVIA RSV vaccine approved 2024; personalized cancer vaccine with Merck shows 44% recurrence reduction in melanoma.
Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stéphane Bancel, and others in Cambridge, Massachusetts, where it is headquartered and trades on Nasdaq (MRNA). The company achieved extraordinary commercial success with Spikevax, its COVID-19 mRNA vaccine developed in partnership with the U.S. government in 2020—generating $18.4 billion in COVID vaccine revenues in 2022 at peak—before experiencing a severe revenue decline as global COVID booster demand normalized. For FY2024, Moderna generated approximately $3.2 billion in revenues, with Spikevax and the reformulated XBB.1.5-targeting COVID vaccine contributing the majority, while the company's significant R&D investment pipeline consumed most operating cash flows.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.